An interventional study of Quit Card Intervention (QCI) in Nicotine Dependence, Cigarettes and Nicotine Withdrawal, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Tobacco Use Disorder with a site in Canada — 10 open to participants now, 10 under way, 1 of them phase 3. Tobacco Use Disorder · Canada.
Among the 43 studies in Tobacco Use Disorder with a site in Canada, this one is the 3rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2022, is one of 19 with no phase, and was the 34th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →10 of the 43 studies in Tobacco Use Disorder with a site in Canada are open now. Recruiting first, the newest first:
St. Justine's Hospital · Sites in Canada
Ages 18+
Waypoint Centre for Mental Health Care · Sites in Canada
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–85
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 3 · Phase 4 9
First in 2005; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,208 is above the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 43 across the 41 interventional studies, 180 across the 2 observational. Of the 28 that completed or were terminated, 7 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 43 has an industry lead sponsor. The 10 most frequent:
Ottawa Heart Institute Research Corporation is the lead sponsor of 182 studies on the registry; 42 are open to participants now.
Ottawa Heart Institute Research Corporation has 2 studies filed under Tobacco Use Disorder — fewer than ten, so there is no comparison to draw.
5 of the studies in Tobacco Use Disorder with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03249428Ottawa Hospital Research InstituteCytisine vs Nicotine Replacement Therapy | 2027-03 |
| NCT03506867Ottawa Hospital Research InstituteHealthy People Initiative (HPI) | 2027-03-31 |
| NCT06346028Centre for Addiction and Mental HealthImplementation of Transcranial Magnetic Stimulation for Smoking Cessation | 2027-06-30 |
| NCT04163081Ottawa Heart Institute Research CorporationThe INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Tobacco Use Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study intervention group.
Behavioral: Quit Card Intervention (QCI)
Study control group.
The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist.
Smoking Abstinence
Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test
Time frame: 26 weeks (6 months) after study enrollment
Prolonged Abstinence
Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Point Prevalence Abstinence
Point prevalence smoking abstinence, at 4, and 52 weeks
Time frame: 4, and 52 weeks after study enrollment
Smoking Reduction
Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Number of Quit Attempts
Number of quit attempts since study entry, at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Cessation Medication and/or E-cigarette Use
Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Use of Behavioural Supports
Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Health-Related Quality of Life
Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Time frame: 52 weeks after study enrollment
Health Services Outcomes - ED visits
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Hospital Admissions
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Deaths
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks
Time frame: 4, 26, and 52 weeks after study enrollment
Cost-Effectiveness Ratios
Cost-effectiveness ratios related to health services at 52 weeks
Time frame: 52 weeks after study enrollment
Plan to share: No
Started Apr 2022 (actual). Primary completion is estimated for Sep 2027, 65 months after the start.
Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 65 months is above that.
Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Sep 2027 and completion Mar 2027 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Heart Institute Research Corporation →